ArticleJournal of translational medicine2026
Bioinformatics profiling of NECTIN4 in lung cancer and comparative evaluation of NECTIN4-targeted ⁶⁸Ga-N188 and ¹⁸F-FDG PET/CT.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe nectin cell adhesion molecule 4 (NECTIN4) has been implicated in tumor progression and immune evasion, yet its role and translational targeted imaging potential in lung cancer remain unclear. Therefore, this study aims to elucidate the significance of NECTIN4 by integrating multi-omics analyses, and to evaluate the diagnostic efficacy of the NECTIN4-targeted PET/CT imaging in lung cancer.
methodsTranscriptomic and proteomic datasets from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO) and other bioinformatic tools were used to characterize NECTIN4 expression, genomic alterations, epigenetic regulation, and prognostic relevance in lung cancer. Subsequently, in a prospective clinical cohort study involving 20 patients with suspected primary lung cancer, paired PET/CT imaging using 68Ga-N188 and 18F-FDG was conducted. Diagnostic performances were assessed by quantitatively comparing the tumor-to-blood pool ratio between malignant and inflammatory lesions.
resultsBioinformatics analyses indicated that NECTIN4 was significantly upregulated across multiple cancer types and correlated with genomic instability and poor prognosis in non-small cell lung cancer (NSCLC). NECTIN4 expression was positively associated with DNA methyltransferases and RNA modifications, suggesting that it may be regulated by epigenetic and post-transcriptional. As for NECTIN4-targeted imaging, ⁶⁸Ga-N188 PET/CT exhibited superior specificity (100% vs. 50%) and comparable sensitivity (87.5% vs. 93.8%) to ¹⁸F-FDG PET/CT in differentiating malignant from inflammatory lung lesions, but with lower sensitivity (42.2% vs. 100.0%) for detecting lymph node metastases and fewer identified distant metastatic lesions (21 vs. 51).
conclusionIntegrated bioinformatics analyses prove that overexpression of NECTIN4 is associated with occurrence and progression of lung cancer. Further preliminary clinical translation study suggests the potential of NECTIN4-targeted radiotracer ⁶⁸Ga-N188 to aid in the differential diagnosis of lung cancer, highlighting a promising clinical application warrants further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.